Clinical Trials
305 trialsNCT04980495 2026-05-27
ADAPT NXT
argenx
Phase 3 Completed
NCT06517758 2026-05-27
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
Novartis
Phase 3 Recruiting
NCT06744920 2026-05-27
RELIEVE
Novartis
Phase 3 Recruiting
NCT06958939 2026-05-27
The Safety and Efficacy of S103 in the Treatment of Refractory Generalized Myasthenia Gravis
Tang-Du Hospital
Phase 1 Active not recruiting
NCT06463587 2026-05-22
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 3 Recruiting
NCT07039916 2026-05-22
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Immunovant Sciences GmbH
Phase 3 Recruiting
NCT07246564 2026-05-22
Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis
UCB Pharma
Phase 4 Recruiting
NCT07595653 2026-05-19
POEMA
argenx
Recruiting
NCT07596784 2026-05-19
Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)
Alexion Pharmaceuticals, Inc.
Phase 3 Not yet recruiting
NCT07596901 2026-05-19
Study of Aritinercept in Patients With Generalized Myasthenia Gravis
Aurinia Pharmaceuticals Inc.
Phase 1/2 Recruiting
NCT00704626 2026-05-18
SAA
University of California, Davis
Enrolling by invitation
NCT06359041 2026-05-18
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
Cabaletta Bio
Phase 1/2 Active not recruiting
NCT06680037 2026-05-18
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
TG Therapeutics, Inc.
Phase 1 Recruiting
NCT07501702 2026-05-18
ETNA
Vertex Pharmaceuticals Incorporated
Phase 2 Recruiting
NCT07593911 2026-05-18
ArchAid-002
Beijing GoBroad Hospital
Phase NA Not yet recruiting
NCT04524273 2026-05-15
MINT
Amgen
Phase 3 Active not recruiting
NCT06193889 2026-05-15
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
Kyverna Therapeutics
Phase 2/3 Recruiting
NCT06909253 2026-05-15
MG-ARCADIA
AstraZeneca
Recruiting
NCT06987539 2026-05-14
THYME
Amgen
Phase 2 Recruiting
NCT07247279 2026-05-13
Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia
AstraZeneca
Recruiting
NCT07337785 2026-05-12
CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
Tongji Hospital
Phase EARLY_PHASE1 Recruiting
NCT07526493 2026-05-12
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
Tongji Hospital
Phase 1 Recruiting
NCT07570589 2026-05-11
REAL MG PRO
Centre Hospitalier Universitaire de Nice
Not yet recruiting
NCT06055959 2026-05-08
ziMyG
UCB Pharma
Phase 2/3 Recruiting
NCT06149559 2026-05-08
roMyG
UCB Pharma
Phase 2/3 Recruiting
NCT06435312 2026-05-08
ziMyG+
UCB Pharma
Phase 3 Enrolling by invitation
NCT06540144 2026-05-08
An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis
UCB Pharma
Phase 3 Enrolling by invitation
NCT06866652 2026-05-08
MyaRESP
Institut de Myologie, France
Recruiting
NCT07217587 2026-05-08
EPIC
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT06456580 2026-05-07
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
Vor Biopharma
Phase 3 Recruiting
NCT07085676 2026-05-06
Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
Hadassah Medical Organization
Phase 1 Recruiting
NCT07571525 2026-05-06
TAILOR-MG
IRCCS San Raffaele
Not yet recruiting
NCT06447597 2026-04-30
A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 2/3 Recruiting
NCT07556120 2026-04-29
Efficacy and Safety of HN2301 in Patients With Generalized Myasthenia Gravis (MG)
Shenzhen MagicRNA Biotechnology Co., Ltd
Phase 1 Not yet recruiting
NCT05332210 2026-04-28
Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis
Harbour BioMed (Guangzhou) Co. Ltd.
Phase 3 Completed
NCT06392386 2026-04-27
ADAPT Jr SC
argenx
Phase 2/3 Recruiting
NCT04225871 2026-04-24
RAISE-XT
UCB Pharma
Phase 3 Active not recruiting
NCT05374590 2026-04-23
ADAPT Jr +
argenx
Phase 2/3 Enrolling by invitation
NCT07284420 2026-04-23
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
argenx
Phase 2 Recruiting
NCT07294170 2026-04-23
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
argenx
Recruiting
NCT05556096 2026-04-21
Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT07304154 2026-04-21
A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
Gilead Sciences
Phase 1 Recruiting
NCT05644561 2026-04-17
Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT06312644 2026-04-16
Study of UltomirisĀ® (Ravulizumab) Safety in Pregnancy
Alexion Pharmaceuticals, Inc.
Recruiting
NCT07532707 2026-04-16
Efficacy of IVIG Versus PLEX in Myasthenic Crisis in Syria.
Damascus University
Phase NA Completed
NCT06414954 2026-04-13
SYNAPSE-MG
NMD Pharma A/S
Phase 2 Recruiting
NCT06754020 2026-04-13
TCM Tongue Diagnosis and Syndrome Differentiation in Myasthenia Gravis Compared to Healthy Controls
National Taipei University of Nursing and Health Sciences
Phase NA Recruiting
NCT07221838 2026-04-09
OCTAGON
Alexion Pharmaceuticals, Inc.
Phase 4 Recruiting
NCT07249632 2026-04-09
A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)
RemeGen Co., Ltd.
Phase 3 Recruiting
NCT07499323 2026-04-08
Talquetamab in Patients With Refractory Generalized Myasthenia Gravis
First Affiliated Hospital of Chongqing Medical University
Phase NA Not yet recruiting